These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 11443512)

  • 1. Gastrointestinal side effects of orlistat may be prevented by concomitant prescription of natural fibers (psyllium mucilloid).
    Cavaliere H; Floriano I; Medeiros-Neto G
    Int J Obes Relat Metab Disord; 2001 Jul; 25(7):1095-9. PubMed ID: 11443512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study.
    Muls E; Kolanowski J; Scheen A; Van Gaal L;
    Int J Obes Relat Metab Disord; 2001 Nov; 25(11):1713-21. PubMed ID: 11753595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia.
    Micić D; Ivković-Lazar T; Dragojević R; Jorga J; Stokić E; Hajduković Z
    Med Pregl; 1999; 52(9-10):323-33. PubMed ID: 10624380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor.
    Finer N; James WP; Kopelman PG; Lean ME; Williams G
    Int J Obes Relat Metab Disord; 2000 Mar; 24(3):306-13. PubMed ID: 10757623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A one-year trial to assess the value of orlistat in the management of obesity.
    James WP; Avenell A; Broom J; Whitehead J
    Int J Obes Relat Metab Disord; 1997 Jun; 21 Suppl 3():S24-30. PubMed ID: 9225173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
    Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.
    Toplak H; Ziegler O; Keller U; Hamann A; Godin C; Wittert G; Zanella MT; Zúñiga-Guajardo S; Van Gaal L
    Diabetes Obes Metab; 2005 Nov; 7(6):699-708. PubMed ID: 16219013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group.
    Rössner S; Sjöström L; Noack R; Meinders AE; Noseda G
    Obes Res; 2000 Jan; 8(1):49-61. PubMed ID: 10678259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity.
    Krempf M; Louvet JP; Allanic H; Miloradovich T; Joubert JM; Attali JR
    Int J Obes Relat Metab Disord; 2003 May; 27(5):591-7. PubMed ID: 12704403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized double-blind study comparing the efficacy and safety of orlistat versus placebo in obese patients with mild to moderate hypercholesterolemia.
    de Castro JJ; Dias T; Chambel P; Carvalheiro M; Correia LG; Guerreiro L; Marques O; Medina JL; Nobre E; Nunes JS; Pereiraa MC; Polónia J; Portugal J; Raimundo A; Ruas A; da Silva PM; Vasconcelos C; Reis JL; Teles AG
    Rev Port Cardiol; 2009 Dec; 28(12):1361-74. PubMed ID: 20301983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Orlistat maintains biliary lipid composition and hepatobiliary function in obese subjects undergoing moderate weight loss.
    Trouillot TE; Pace DG; McKinley C; Cockey L; Zhi J; Häeussler J; Guerciolini R; Showalter R; Everson GT
    Am J Gastroenterol; 2001 Jun; 96(6):1888-94. PubMed ID: 11421247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study.
    Richelsen B; Tonstad S; Rössner S; Toubro S; Niskanen L; Madsbad S; Mustajoki P; Rissanen A
    Diabetes Care; 2007 Jan; 30(1):27-32. PubMed ID: 17192328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of orlistat on cardiovascular disease risk in obese adults.
    Swinburn BA; Carey D; Hills AP; Hooper M; Marks S; Proietto J; Strauss BJ; Sullivan D; Welborn TA; Caterson ID
    Diabetes Obes Metab; 2005 May; 7(3):254-62. PubMed ID: 15811142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weight loss in obese Mexican Americans treated for 1-year with orlistat and lifestyle modification.
    Poston WS; Reeves RS; Haddock CK; Stormer S; Balasubramanyam A; Satterwhite O; Taylor JE; Foreyt JP
    Int J Obes Relat Metab Disord; 2003 Dec; 27(12):1486-93. PubMed ID: 14634679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The long-term influence of orlistat on dietary intake in obese subjects with components of metabolic syndrome.
    Svendsen M; Helgeland M; Tonstad S
    J Hum Nutr Diet; 2009 Feb; 22(1):55-63. PubMed ID: 19192027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial.
    Davidson MH; Hauptman J; DiGirolamo M; Foreyt JP; Halsted CH; Heber D; Heimburger DC; Lucas CP; Robbins DC; Chung J; Heymsfield SB
    JAMA; 1999 Jan; 281(3):235-42. PubMed ID: 9918478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients.
    Derosa G; Cicero AF; Murdolo G; Piccinni MN; Fogari E; Bertone G; Ciccarelli L; Fogari R
    Diabetes Obes Metab; 2005 Jan; 7(1):47-55. PubMed ID: 15642075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial.
    Harrison SA; Fecht W; Brunt EM; Neuschwander-Tetri BA
    Hepatology; 2009 Jan; 49(1):80-6. PubMed ID: 19053049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety profile of orlistat: results of a prescription-event monitoring study.
    Acharya NV; Wilton LV; Shakir SA
    Int J Obes (Lond); 2006 Nov; 30(11):1645-52. PubMed ID: 16552401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipase inhibition: a novel concept in the treatment of obesity.
    Drent ML; van der Veen EA
    Int J Obes Relat Metab Disord; 1993 Apr; 17(4):241-4. PubMed ID: 8387973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.